10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

DEFA14A - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

DEF 14A - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

SCHEDULE 13G/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

SCHEDULE 13G - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

S-8 - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

10-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

3 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

Former NFL quarterback and 2026 Hall of Fame inductee highlights daily life for people living with severe food allergies and role preparedness plays in living fully Collaboration focuses on education around the importance of epinephrine and treatment options for severe allergic reactions, including anaphylaxis SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against allergic reactions that could lead to anaphylaxis, today announced a new collaboration with Drew Brees, former NFL quarterback, Super Bowl champion, 2026 Hall of Fame inductee and father of

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June Sales force expansion to 148 representatives completed Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients against allergic reactions that could lea

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe allergic reactions that can lead to anaphylaxis, today announced the appointment of Donn Casale as President, effective June 1, 2026. Richard Lowenthal will continue to lead ARS Pharma as Chief Executive Officer. Mr. Casale is a 25-year biopharmaceutical commercial leader with extensive experience scaling innovative products in large consumer-driven healthcare markets, including categories where patients seek therapies that help reduce the risk of future serious medical events. As President,

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Friday, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2026 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website. A repl

neffy offers a new delivery method for epinephrine in Canada for adults and children (>30 kg) living with severe allergic reactions ALK- Abelló A/S, which licenses the rights to market neffy in Canada, expects availability in the summer of 2026 SAN DIEGO, April 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect against allergic reactions that could lead to anaphylaxis, announced today that Health Canada has granted approval for neffy 2 mg (epinephrine nasal spray) for the emergency treatment of allergic reactions (anaphylaxis) in adults and children who weigh 30

Children were previously required to weigh ≥33 lbs. and <66 lbs. and be at least four years of age to receive neffy 1 mg dose - approval enables families of younger children within the weight range to access a needle-free epinephrine without age restrictions Updated labeling recommends storage in blister packaging or a neffy carrying case; ARS Pharma currently makes carrying cases available and will include one with each prescription beginning this summer SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that cou

neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even  Conference call to be held today, March 9, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced financial results for t

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. In addition, ARS Pharma Management will be participating at several upcoming investor conferences: 10th Annual Oppenheimer Emer

-Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more affordable, value-based price -When factoring in patients' dislike of needle-based administration, the value of a nasal option increased by more than 25% SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that five poste

EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma's partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute following expected authorization by the European Commission SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recomme

Northland Capital initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $25.00

Roth Capital resumed coverage of ARS Pharmaceuticals with a rating of Buy and set a new price target of $30.00

Roth Capital initiated coverage of ARS Pharmaceuticals with a rating of Buy and set a new price target of $40.00

Scotiabank initiated coverage of ARS Pharmaceuticals with a rating of Sector Outperform and set a new price target of $30.00

Oppenheimer initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $40.00

Cantor Fitzgerald initiated coverage of ARS Pharmaceuticals with a rating of Overweight

Raymond James upgraded ARS Pharmaceuticals from Outperform to Strong Buy and set a new price target of $22.00 from $18.00 previously

Leerink Partners reiterated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $20.00 from $19.00 previously

Raymond James initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $18.00

Leerink Partners upgraded ARS Pharmaceuticals from Market Perform to Outperform and set a new price target of $18.00 from $6.00 previously

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe allergic reactions that can lead to anaphylaxis, today announced the appointment of Donn Casale as President, effective June 1, 2026. Richard Lowenthal will continue to lead ARS Pharma as Chief Executive Officer. Mr. Casale is a 25-year biopharmaceutical commercial leader with extensive experience scaling innovative products in large consumer-driven healthcare markets, including categories where patients seek therapies that help reduce the risk of future serious medical events. As President,

– Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of their innovations – SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced the appointment of Laura Shawver, Ph.D., as Chair of its Board of Directors. "We are honored to welcome Dr. Shawver to our Board. Laura's outstanding track record of driving strategic growth and developing innovative therapies comes at a pivotal time as we scale to advance our pipeline and expand the impact of our next-generation

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June Sales force expansion to 148 representatives completed Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients against allergic reactions that could lea

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Friday, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2026 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website. A repl

neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even  Conference call to be held today, March 9, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced financial results for t

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. In addition, ARS Pharma Management will be participating at several upcoming investor conferences: 10th Annual Oppenheimer Emer

$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world evidence, expected to accelerate with seamless prescribing experience Strong balance sheet of $288.2 million cash, cash equivalents and short-term investments anticipated to fund operations through cash-flow break-even Conference call to be held today, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m. ET  SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better pro

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its third quarter 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website.

$15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with additional near-term growth anticipated from national direct-to-consumer (DTC) campaign and pediatric co-promote partnership 93% commercial coverage achieved with streamlined prior authorization process with approval rates at the pharmacy benefit manager (PBM) comparable to overall epinephrine market EURneffy® approved in the United Kingdom and launched in Germany, now representing a global footprint with this first and only needle-free epinephrine treatment Conference call to be held today, August 13, 2025, at 5:

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its second quarter 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website

$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle-free treatment for severe allergic reactions including anaphylaxis Conference call to be held today, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website. A repla

SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)